These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29589987)

  • 21. [New therapies in thyroid cancer].
    López Mondéjar P; Galofré JC
    Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
    [No Abstract]   [Full Text] [Related]  

  • 22. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
    Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
    Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
    Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
    Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
    [No Abstract]   [Full Text] [Related]  

  • 24. ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.
    Socinski MA
    Oncology (Williston Park); 2011 Jun; 25(7):601, 604, 607. PubMed ID: 21888259
    [No Abstract]   [Full Text] [Related]  

  • 25. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
    De Falco V; Carlomagno F; Li HY; Santoro M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein kinase inhibitors: novel tools in cancer therapy.
    Marmé D
    Urologe A; 2004 Sep; 43 Suppl 3():S148. PubMed ID: 15148578
    [No Abstract]   [Full Text] [Related]  

  • 27. Cell cycle inhibitors for the treatment of NSCLC.
    Shcherba M; Liang Y; Fernandes D; Perez-Soler R; Cheng H
    Expert Opin Pharmacother; 2014 May; 15(7):991-1004. PubMed ID: 24666387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
    Bunn PA
    J Clin Oncol; 2007 Jun; 25(18):2504-5. PubMed ID: 17577025
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung cancer biomarkers: present status and future developments.
    Cagle PT; Allen TC; Olsen RJ
    Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer.
    Subramanian J; Corrales L; Soulieres D; Morgensztern D; Govindan R
    J Thorac Oncol; 2011 Feb; 6(2):399-403. PubMed ID: 21206384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments].
    Wiewrodt R; Serke M; Grohé C; Brückl W
    Pneumologie; 2013 Sep; 67(9):494-501. PubMed ID: 24006195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Crizotinib - molecular therapy for lung cancer].
    Gröschel A; Warth A; Reinmuth N
    Pneumologie; 2013 Apr; 67(4):205-8. PubMed ID: 23576200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resensitizing Refractory ALK+ NSCLC: A Case Study.
    Poh A
    Cancer Discov; 2016 Mar; 6(3):220-1. PubMed ID: 26801737
    [No Abstract]   [Full Text] [Related]  

  • 38. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 40. How should "RET positive" NSCLC be treated?
    Smit EF
    Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.